SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: I_Banker1/8/2005 3:16:36 PM
  Read Replies (1) of 371
 
I was talking to an oncologist who was a former investor in IMMU and he told me to steer clear of the company. I asked him why, and he said that the company had a habit of hyping products that didn't work. He explained that Amgen returned the rights to CD-22 to IMMU after they concluded in their clinical trial that there was no measurable benefit to the combination therapy.

Is this characterization accurate? Did Amgen walk away from CD-22 after seeing the results of clinical trials involving the combination therapy? If so, what is the danger that this Lupus thing is a hype as well?

Thanks to anyone who can shed light.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News